Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 243

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Comment on Comparison of the Low Dose Short Synacthen Test (1μ g), the Conventional Dose Short Synacthen Test (250 μg), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients with Pituitary Disease1

Open access
Oelkers, Wolfgang · 1999 · The Journal of Clinical Endocrinology & Metabolism

Abstract

In their recent paper, Abdu et al. (1) compared the low dose short synacthen test (1 μg, LDSST) and the high dose (250 μg, SST) ACTH-test in patients with confirmed pituitary disease with results of the insulin tolerance test (ITT). Using an arbitrary plasma cortisol cut-off point 30 min after ACTH 1–24 injection of 600 nmol/L as the criterion of a sufficient or insufficient response, they found the sensitivity of the LDSST as well as the SST for the diagnosis of secondary adrenal insufficiency to be 100%, while the specificity was 80% and 77%, respectively. This difference in specificity is negligible. The authors misquote our recently published paper (2), in which we reported that the sensitivity and specificity of the LDSST and the SST were identical, if different plasma cortisol cut-off levels were being used for the two tests. These cut-off levels were determined in a large group of normal subjects in our endocrinological center. Contrary to their quotation on page 842 of their paper (1), 23 (not 14) out of 44 patients with pituitary disease in our study had subnormal responses in the reference tests (ITT or metyrapone tests). Both the LDSST and the SST failed to identify 8 of these patients (sensitivity, 65%), most of whom had slightly subnormal reference tests. The specificity of both tests was 96%. We used 550 nmol/L as the cortisol cut-off point for the ITT and 200 nmol/L for the 11-deoxycortisol response in the metyrapone test. Our slightly higher cut-off point for the ITT, compared with 500 nmol/L used by Abdu et al. (1), is justified because (2) we had recently performed ITTs in 25 normal subjects, all of whom had a plasma cortisol maximum of ≥600 nmol/L, as stated in our recent correspondence (3) regarding the paper by Mayenknecht et al. (2). We do not understand why Abdu et al., based on their own findings, come to the conclusion that the LDSST should replace the SST and the ITT as a screening test for secondary adrenal insufficiency. Abdu et al. and Mayenknecht et al. did their studies in a meticulous and standardized way. Internists or endocrinologists not familiar with the LDSST may run into trouble diluting the content of a 250 μg ACTH 1–24 ampoule, or, if a 1 μg ampoule should be on the market, adhering ACTH to plastic tubing or glass, as recently reported by Murphy et al. (4). Furthermore, the cortisol maximum in the LDSST is variable, as pointed out by Abdu et al. (1), due to the very short lasting stimulation of the adrenal by the 1 μg dose of ACTH 1–24 in the LDSST (2). To diagnose primary adrenal insufficiency or adrenal insufficiency in intensive care patients, we would continue to use the standard SST. Why should we introduce the LDSST into clinical practice as a screening test for secondary adrenal insufficiency if it is no better than the standard SST? Short ACTH tests as screening tests for secondary adrenal insufficiency are problematical, as pointed out by Streeten (5) in the editorial accompanying the paper by Abdu et al. and by our group (2, 3, 6). The authors of the article under discussion rightly state that the SST and the LDSST (with a relatively high cortisol cut-off point), if used in conjunction with clinical information, may obviate the performance of the more cumbersome ITT in several patients. Because the diagnostic efficiency of both short ACTH tests is almost identical and the conventional SST carries no risk related to the high dose of ACTH 1–24, there is no need to replace it with the LDSST. For reasons outlined earlier, it is unlikely that an ACTH test with a dose still smaller than 1 μg would do a better job (2, 6).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jcem.84.8.5939-1

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 243

Metadata

Authors
Oelkers, W.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1999-08
Volume
84
Issue
8
Pages
2973-2973
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2133301528
Cited by
243
References
11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comment on Comparison of the Low Dose Short Synacthen Test (1μ g), the Conventional Dose Short Synacthen Test (250 μg), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients with Pituitary Disease1. https://app.cochat.ai/papers/10.1210/jcem.84.8.5939-1
The paper
Oelkers, W. (1999). Comment on Comparison of the Low Dose Short Synacthen Test (1μ g), the Conventional Dose Short Synacthen Test (250 μg), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients with Pituitary Disease1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.84.8.5939-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.